Table 3.

Vaccine efficacy and effectiveness (at least one dose) in adult women (>26 years old).

Vaccine Type	Efficacy and Effectiveness	HPV Status at Enrolment	Vaccine Efficacy (95% CI)
Bivalent	Persistent infection from HPV 16/18 (6 months) [15,56]	Naive	83% (71% to 90%)
		Irrespective	43% (31% to 53%)
	CIN2+ associated with HPV 16/18 [15]	Naive	70% (19% to 89%)
		Irrespective	26% (−5% to 48%)
Quadrivalent	Persistent infection from HPV 6/11/16/18 (6 months) [15]	Irrespective	48% (35% to 58%)
	CIN2+ associated with HPV 6/11/16/18 [15]	Naive	63% (−41% to 90%)
		Irrespective	22% (−37% to 56%)
	All CIN and external genital lesions related to HPV 6/11/16/18 [57]	Naive	88.7% (71.8% to 94.8%)
		Irrespective	30.9% (11.1% to 46.5%)
	Incidence of infection of at least 6 months’ duration and cervical and external genital disease related to HPV 6/11/16/18 [57]	Naive	74·6% (58.1% to 85%)
		Irrespective	30.9% (11.1% to 46.5%)